Navigation Links
New dual recognition mechanism discovered in tuberculosis

One third of the world's population is infected with Mycobacterium tuberculosis (MTB), which leads to tuberculosis (TB), a leading cause of death world-wide. A new discovery, led by a team of researchers from Case Western Reserve University School of Medicine, offers hope for new approaches to the prevention and treatment of TB. The team's discovery of a novel mechanism that may contribute to immune recognition of MTB is published in the September issue of Nature Structural and Molecular Biology.

Most individuals with TB recover from the initial infection and become asymptomatic, but the bacterium persists for years, surviving largely inside macrophages, a type of cell that resides in the immune system. This presents a public health problem in that TB can reactivate and cause serious disease or death. Researchers and physicians know the body's immune system is capable of containing the infection but not curing it completely. It begs the question: "How does the organism survive in the human immune system for so many years?"

For the past 15 years, Drs. Clifford Harding and W. Henry Boom of Case Western Reserve have been seeking the answer to this question. Their work indicated that MTB can inhibit the ability of macrophages to stimulate infection-fighting immune responses, and they identified that a protein on macrophages called Toll-like receptor 2 (TLR2) is involved in this immune evasion mechanism. TLR2 seems to be a two-edged sword in the complex immune response to MTB, as it helps some immunity mechanisms and inhibits others. Understanding the balance of these effects and the role of TLR2 may provide insights to design therapies for TB.

"Understanding how MTB interacts with the immune system and how it can both activate and inhibit the immune response is critically important for the design of the next generation of TB vaccines. The persistence of infection is dependent on MTB's ability to manipulate our immune system to its advantage. The paradox here is that the MTB molecule, LprG, stimulates TLR2, one of the major receptors we have to identify disease-causing microorganisms. In this case, too much stimulation through TLR2 actually favors MTB by causing parts of the immune response to shut down," explains W. Henry Boom, MD, professor of medicine and director of the Tuberculosis Research Unit at Case Western Reserve School of Medicine.

The new studies show that the potency of LprG to induce these responses is explained by its combination of two mechanisms to activate TLR2: first, by directly stimulating TLR2 and, second, by serving as a carrier to deliver other molecules that stimulate TLR2. This dual mechanism may drive stronger regulation of immune responses by MTB, and future vaccine development may be enhanced by designing approaches to use such mechanisms. Furthermore, the work indicates that LprG contributes to the assembly of the bacterial cell wall, suggesting that it may be possible to develop molecules to interfere with LprG function and potentially serve as new antibiotics to fight TB. The development of new antibiotics is an increasingly important goal, since resistance to existing antibiotics is becoming widespread.

A multi-institutional partnership contributed to the overall success of this research initiative. Two important collaborative groups were led by James C. Sacchettini, PhD, Texas A&M University and D. Branch Moody, MD, Harvard Medical School. In addition, the project was spearheaded by Michael G. Drage and Nicole D. Pecora, two Case Western Reserve students in the MSTP Program, granting dual MD and PhD degrees, in collaboration with Jennifer Tsai, a graduate student in Dr. Sacchettini's group.

"Our research team is composed of several collaborative groups that each contributed key components to this project. The synergistic way in which the team interacted was a perfect example of scientists working together to advance the study of a disease that detrimentally impacts the lives of so many across the globe. We look forward to continuing to advance this research together," says Clifford V. Harding, MD, PhD, professor and interim chair of pathology at Case Western Reserve School of Medicine.

As they look to the future, the research team will work to gain a better understanding of immune responses in TB and hopefully design approaches to treat the deadly disease, including antibiotics or immunotherapies. Continued work will include study of the mechanism of immune-evasion by MTB with the hope of finding ways to reverse this mechanism so that it no longer causes a persistent infection.


Contact: Jessica Studeny
Case Western Reserve University

Related medicine news :

1. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
2. Christiana Care Health System Achieves Magnet(R) Recognition
3. Pelosi Statement in Recognition of Women’s History Month
4. Quantros Releases Video in Recognition of National Patient Safety Week
5. Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting
6. US Wellness, Inc. Receives National Recognition for Laboratory Excellence
7. Medical Billers Celebrate Official Day Of Recognition On March 25, 2010 - USA
8. Prestigious recognition award recipients announced by AGA
9. Nursefinders Announces “Best Nurses of Baltimore” Recognition Program
10. ASGE recognizes 48 endoscopy units for quality as part of its Endoscopy Unit Recognition Program
11. Recognition at first glance
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... – Kreithen”), one of the leading plastic surgery practices in Florida, is proud ... chosen to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational New ... is so important to this key industry segment, Regis Technologies has decided to sponsor ... December 4th at 11am EST. , Federal law does not allow new drugs to ...
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced ... a Healthcare IT consulting, development and support company. The purchase will expand the ... within DataTrade to extend the services currently provided by Healthjump. , ...
(Date:11/30/2015)... ... , ... GKhair & Tibolli team members and artists were excited and proud ... 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto Rico. The ... of the line fashion journalists. The San Juan Beauty Show carries immense credibility among ...
(Date:11/30/2015)... Georgia (PRWEB) , ... November 30, 2015 , ... ... for healthcare professionals worldwide today released the results of a survey of educational ... East and Africa found a growing global demand for high quality online and ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... YORK , Nov. 30, 2015 Cumberland Pharmaceuticals ... will present live at on December 3, 2015. ... --> TIME: 3:15p.m. ET LINK: ... ET LINK: --> ... online event where investors are invited to ask the company ...
(Date:11/30/2015)... Nov. 30, 2015 Varian Medical Systems (NYSE: VAR ... educational partnership with Apollo Hospitals Group, the largest hospital chain in ... help train radiation technologists in the country. The MoU was signed ... Knowledge, and Ashok Kakkar , Varian,s India ... India , Varian intends to deploy its Access ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
Breaking Medicine Technology: